Literature DB >> 16757431

Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy.

Kensuke Naito1, Miki Kobayashi, Naohi Sahara, Kazuyuki Shigeno, Satoki Nakamura, Kaori Shinjo, Tadasu Tobita, Akihiro Takeshita, Ryuzo Ohno, Kazunori Ohnishi.   

Abstract

We describe 2 patients with acute promyelocytic leukemia (APL) in whom torsade de pointes (TdP) developed during treatment with arsenic trioxide. Patient 1 was a 23-year-old woman with second-relapse APL. Ventricular premature beat bigeminy developed on day 27 of treatment, and episodes of TdP developed on day 28. Patient 2 was a 51-year-old woman with second-relapse APL who had cardiomyopathy due to prior anthracycline treatment. TdP developed on day 17 of treatment. Arsenic trioxide is known to cause electrocardiographic abnormalities, such as ventricular tachycardia and prolongation of QT interval. Patient 1 was given fluconazole as a concomitant drug. Patient 2 had cardiomyopathy and hypokalemia. Careful management is needed during arsenic trioxide therapy because this treatment prolongs the QT interval, possibly inducing episodes of TdP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16757431     DOI: 10.1532/IJH97.05056

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  14 in total

1.  The electrocardiogram in acute arsenic poisoning.

Authors:  S L WEINBERG
Journal:  Am Heart J       Date:  1960-12       Impact factor: 4.749

2.  Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.

Authors:  K Ohnishi; H Yoshida; K Shigeno; S Nakamura; S Fujisawa; K Naito; K Shinjo; Y Fujita; H Matsui; A Takeshita; S Sugiyama; H Satoh; H Terada; R Ohno
Journal:  Ann Intern Med       Date:  2000-12-05       Impact factor: 25.391

3.  Ventricular fibrillation caused by arsenic poisoning.

Authors:  J St Petery; C Gross; B E Victorica
Journal:  Am J Dis Child       Date:  1970-10

4.  Torsade de pointes and T-U wave alternans associated with arsenic poisoning.

Authors:  R E Little; G N Kay; J B Cavender; A E Epstein; V J Plumb
Journal:  Pacing Clin Electrophysiol       Date:  1990-02       Impact factor: 1.976

5.  Arsenic-induced atypical ventricular tachycardia.

Authors:  S Goldsmith; A H From
Journal:  N Engl J Med       Date:  1980-11-06       Impact factor: 91.245

6.  Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.

Authors:  D Unnikrishnan; J P Dutcher; N Varshneya; R Lucariello; M Api; S Garl; P H Wiernik; S Chiaramida
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

7.  Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring.

Authors:  K Ohnishi; H Yoshida; K Shigeno; S Nakamura; S Fujisawa; K Naito; K Shinjo; Y Fujita; H Matsui; N Sahara; A Takeshita; H Satoh; H Terada; R Ohno
Journal:  Leukemia       Date:  2002-04       Impact factor: 11.528

8.  Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.

Authors:  S L Soignet; P Maslak; Z G Wang; S Jhanwar; E Calleja; L J Dardashti; D Corso; A DeBlasio; J Gabrilove; D A Scheinberg; P P Pandolfi; R P Warrell
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

9.  Mechanisms of arsenic-induced prolongation of cardiac repolarization.

Authors:  Eckhard Ficker; Yuri A Kuryshev; Adrienne T Dennis; Carlos Obejero-Paz; Lu Wang; Peter Hawryluk; Barbara A Wible; Arthur M Brown
Journal:  Mol Pharmacol       Date:  2004-07       Impact factor: 4.436

10.  Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents.

Authors:  Benoit Drolet; Chantale Simard; Dan M Roden
Journal:  Circulation       Date:  2003-12-22       Impact factor: 29.690

View more
  6 in total

Review 1.  Drug-induced mitochondrial dysfunction and cardiotoxicity.

Authors:  Zoltán V Varga; Peter Ferdinandy; Lucas Liaudet; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-18       Impact factor: 4.733

Review 2.  Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer.

Authors:  Richard L Carpenter; Haimanti Ray
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.606

3.  QTc prolongation assessment in anticancer drug development: clinical and methodological issues.

Authors:  G Curigliano; G Spitaleri; F de Braud; D Cardinale; C Cipolla; M Civelli; N Colombo; A Colombo; M Locatelli; A Goldhirsch
Journal:  Ecancermedicalscience       Date:  2009-01-12

Review 4.  Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: current evidence and future research perspectives.

Authors:  Jialin Duan; Jingwen Tao; Maocai Zhai; Chengpeng Li; Ning Zhou; Jiagao Lv; Lin Wang; Li Lin; Rong Bai
Journal:  Oncotarget       Date:  2018-05-22

5.  Salvianolic Acid B prevents arsenic trioxide-induced cardiotoxicity in vivo and enhances its anticancer activity in vitro.

Authors:  Min Wang; Guibo Sun; Ping Wu; Rongchang Chen; Fan Yao; Meng Qin; Yun Luo; Hong Sun; Qiang Zhang; Xi Dong; Xiaobo Sun
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-08       Impact factor: 2.629

6.  Endothelial to mesenchymal transition contributes to arsenic-trioxide-induced cardiac fibrosis.

Authors:  Yong Zhang; Xianxian Wu; Yang Li; Haiying Zhang; Zhange Li; Ying Zhang; Longyin Zhang; Jiaming Ju; Xin Liu; Xiaohui Chen; Peter V Glybochko; Vladimir Nikolenko; Philipp Kopylov; Chaoqian Xu; Baofeng Yang
Journal:  Sci Rep       Date:  2016-09-27       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.